THE EFFECT OF SPORTS HEALTH TREATMENT ON REDUCING THE PREVALENCE OF HYPERTENSION

Xiao, Li

doi:10.1590/1517-8692202127032021_0098

Acessibilidade / Reportar erro

Brasil

Revista Brasileira de Medicina do Esporte

Español English

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

ORIGINAL ARTICLE • Rev Bras Med Esporte 27 (3) • Jul-Sep 2021 • https://doi.org/10.1590/1517-8692202127032021_0098 copy

THE EFFECT OF SPORTS HEALTH TREATMENT ON REDUCING THE PREVALENCE OF HYPERTENSION

O EFEITO DO TRATAMENTO DE SAÚDE ESPORTIVA NA REDUÇÃO DA PREVALÊNCIA DE HIPERTENSÃO

EL EFECTO DEL TRATAMIENTO DE SALUD DEPORTIVA EN LA REDUCCIÓN DE LA PREVALENCIA DE HIPERTENSIÓN

Authorship SCIMAGO INSTITUTIONS RANKINGS

ABSTRACT

Introduction

Hypertension is a common clinical disease, which is not uncommon in the aviation industry. Pilots suffering from high blood pressure need to control high blood pressure to ensure flight safety. Exercise therapy is an effective way to control high blood pressure.

Objective

To design the clinical effects of exercise intervention in the treatment of hypertension in pilots.

Method

The article randomly assigned 41 pilot volunteers with hypertension to two groups: the treatment and control groups. Except for the different exercise intervention therapy, the other treatment methods are the same. After the expiration of the experiment, the volunteers were tested for their physiological and biochemical indicators.

Results

After one year of strict diet and exercise intervention, the two groups of physiological and biochemical indicators were significantly different.

Conclusion

Intervention of moderate-intensity exercise can reduce the body mass index, waist-to-hip ratio and blood pressure level of hypertensive patients, correct the disorder of blood lipid metabolism, and can help reduce the recurrence rate of hypertension. Level of evidence II; Therapeutic studies - investigation of treatment results.

Diet Therapy; Exercise Therapy; Hypertension; Sports; Pilots

	Number of cases (n)	Body mass index BMI (kg/m²)
	Number of cases (n)	When joining the group	One month later	Two months later	One year later
Therapy group	26	24.5±2.1	22.4±1.9	22.1±1.8	22.0±1.7
Control group	12	24.5±2.2	24.3±2.3	24.2±2.2	24.2±2.3
F		1.84	3.28	7.58	7.83
P		>0.05	>0.05	<0.05	<0.01
	Number of cases (n)	Waist to hip ratio WHR
	Number of cases (n)	When joining the group	One month later	Two months later	One year later
Therapy group	26	0.9±0.0	0.8±0.0	0.8±0.0	0.8±0.1
Control group	12	0.9±0.1	0.9±0.0	0.9±0.1	0.8±0.1
F		1.79	8.64	9.62	8.46
P		>0.05	<0.01	<0.01	<0.01
	Number of cases (n)	Systolic SBP (mmHg)
	Number of cases (n)	When joining the group	One month later	Two months later	One year later
Therapy group	26	148.8±7.8	142.3±7.3	133.2±6.4	132.6±6.5
Control group	12	148.3±7.7	134.3±6.6	132.6±6.4	131.7±6.3
F		3.28	3.42	2.95	2.67
P		>0.05	>0.05	>0.05	>0.05
	Number of cases (n)	Diastolic blood pressure DBP (mmHg)
	Number of cases (n)	When joining the group	One month later	Two months later	One year later
Therapy group	26	95.6±4.6	89.4±4.3	82.4±4.0	82.2±4.1
Control group	12	95.5±4.6	83.5±4.6	81.9±4.2	81.6±4.2
F		1.99	7.86	1.74	1.64
P		>0.05	<0.01	>0.05	>0.05

	Number of cases (n)	Total cholesterol TC (mmol/L)
	Number of cases (n)	When joining the group	One month later	Two months later	One year later
Therapy group	26	6.15±1.15	4.67±1.06	4.62±0.96	4.65±1.03
Control group	12	6.14±1.17	6.13±1.09	6.08±1.17	6.01±1.03
F		0.58	7.61	9.05	9.18
P		>0.05	<0.05	<0.01	<0.01
	Number of cases (n)	Triglyceride TG (mmol/L)
	Number of cases (n)	When joining the group	One month later	Two months later	One year later
Therapy group	26	2.04±0.43	1.67±0.36	1.63±0.33	1.64±0.29
Control group	12	2.05±0.51	2.02±0.48	2.03±0.43	1.98±0.39
F		1.09	8.13	10.25	9.37
P		>0.05	<0.01	<0.01	<0.01
	Number of cases (n)	Low-density lipoprotein cholesterol LDL-C (mmol/L)
	Number of cases (n)	When joining the group	One month later	Two months later	One year later
Therapy group	26	4.51±1.03	3.09±0.49	3.03±0.38	3.06±0.41
Control group	12	4.49±1.15	4.46±1.07	4.43±1.04	4.45±1.07
F		0.96	8.25	10.36	11.53
P		>0.05	<0.01	<0.01	<0.01
	Number of cases (n)	High-density lipoprotein cholesterol HDL-C (mmol/L)
	Number of cases (n)	When joining the group	One month later	Two months later	One year later
Therapy group	26	0.65±0.16	0.81±0.13	0.85±0.15	0.84±0.20
Control group	12	0.66±0.19	0.67±0.21	0.64±0.15	0.70±0.23
F		0.87	7.47	8.15	7.73
P		>0.05	<0.05	<0.01	<0.05
	Number of cases (n)	Apolipoprotein A-1 ApoA-1(g/L)
	Number of cases (n)	When joining the group	One month later	Two months later	One year later
Therapy group	26	1.13±0.18	1.12±0.14	1.09±0.12	1.11±0.16
Control group	12	1.14±0.24	1.13±0.19	1.10±0.26	1.09±0.22
F		0.89	0.97	0.92	0.9
P		>0.05	>0.05	>0.05	>0.05
	Number of cases (n)	Apolipoprotein BApoB (g/L)
	Number of cases (n)	When joining the group	One month later	Two months later	One year later
Therapy group	26	1.59±0.54	1.25±0.03	1.23±0.05	1.24±0.06
Control group	12	1.61±0.55	1.57±0.06	1.55±0.07	1.50±0.08
F		1.94	8.16	8.74	9.06
P		>0.05	<0.01	<0.01	<0.01

Sociedade Brasileira de Medicina do Exercício e do Esporte Av. Brigadeiro Luís Antônio, 278, 6º and., 01318-901 São Paulo SP, Tel.: +55 11 3106-7544, Fax: +55 11 3106-8611 - São Paulo - SP - Brazil
E-mail: atharbme@uol.com.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] Correspondence: Li Xiao Physical culture institute, Xinyang Normal University, Xinyang, Henan, 464000, China. xiaoli@xynu.edu.cn ,